Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
Uterine endometrial cancer is one of the most common gynecological malignancies worldwide. With relatively few options for late-line therapies for advanced or relapsed endometrial cancer, the use of pretreated therapies may broaden the choice of treatments. Here, we report a case of recurrent micros...
Saved in:
Main Authors: | Kaito Mimura (Author), Akihiko Shimomura (Author), Tomoko Gota (Author), Kenju Ando (Author), Yukino Kawamura (Author), Tomoko Taniyama (Author), Hajime Oishi (Author), Chikako Shimizu (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
by: Mingyang Feng, et al.
Published: (2022) -
Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021) -
A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
by: Naaman Mehta, et al.
Published: (2023) -
Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
by: Peter G. Rose, et al.
Published: (2023) -
1 Examining the immune tumor microenvironment of endometrial cancer patients treated with pembrolizumab plus lenvatinib
by: Erica V. Carballo, et al.
Published: (2023)